Biogen vs Vertex Pharmaceuticals
Vertex Pharmaceuticals is the larger business, with $12.00bn of revenue in fiscal 2025 against $9.89bn for Biogen (1.2 times as much). Vertex Pharmaceuticals grew faster (8.9% against 2.2%). Vertex Pharmaceuticals kept more of each dollar of sales as profit: a net margin of 32.9% against 13.1%.
| Latest fiscal year | BiogenBIIB, 2025 | Vertex PharmaceuticalsVRTX, 2025 |
|---|---|---|
| Revenue | $9.89bn | $12.00bn |
| Revenue growth | 2.2% | 8.9% |
| Net income | $1.29bn | $3.95bn |
| Operating margin | — | — |
| Net margin | 13.1% | 32.9% |
| Return on equity | 7.4% | 22.5% |
| Free cash flow | $2.05bn | $3.19bn |
| Cash | $3.01bn | $5.08bn |
| Total debt | $6.57bn | $0 |
| Debt to equity | 36.0% | — |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | $2.02bn |
| Employees | 7,500 | 6,400 |
| Market value | $36.79bn | $134.42bn |
| Price vs our value range | Within our value range | Above our value range |
| Moat score | 87 (Strong) | 76 (Strong) |
| Insider trades, 12 months | 1 buys, 4 sales | 0 buys, 93 sales |